Breaking News on Global Pharmaceutical Technology & Manufacturing

Top Headlines

Senate Committee OK’s extra $40m to FDA but refuses Obama’s $146m plan

The Senate Committee on Appropriations has approved $2.6bn in funding to the US FDA for FY2016.

The Senate Committee on Appropriations approved a modest increase to FDA funding

Hikma buys B-I generics subsidiary, strengthens position in US market

Hikma says its $2.65bn acquisition of Roxane Laboratories will make it the sixth largest firm in the US generics space.

US FDA finalises analytical procedures and methods validation guidance

Pharma firms may need to carry-out an analytical method comparability study as part of the life cycle management of a drug, according to final US FDA guidelines.


Senior changes at Sanofi-Merck JV, Novo Nordisk, ABPI, and MedImmune

New faces in pharma in our weekly column.


Teva to buy Allergan's generics biz for $40.5bn

Teva has struck a deal to buy Allergan’s generics business a week after its persistent attempts to acquire Mylan fell through.

Less than a year to risk assess excipients: IPEC Europe develops 'how to' guide

IPEC Europe has reminded drugmakers they have less than a year to risk assess all excipients used in their products under recently introduced EU rules.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...